Oryzon Genomics S.A.

4 trials 3 recruiting Commercial sponsor

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

3 Recruiting

0 Completed trials

6 Countries active

2 Unique IMPs

N/A Results reported

Phase II

Phase I (Other)

Phase II: 2 Phase I (Other): 2

Top indications

Schizophrenia 1

Top IMPs

IADADEMSTAT 1 VAFIDEMSTAT 1

All trials

4 total

A PHASE 1, OPEN-LABEL STUDY TO ASSESS THE ABSORPTION, DISTRIBUTION, METABOLISM, AND EXCRETION, INCLUDING THE MASS BALANCE, OF A SINGLE ORAL … Pending

2025-524832-20-00 Phase I (Other) 1 country
Phase 2 Study of iadademstat for the treatment of patients with essential thrombocythemia resistant/intolerant to hydroxyurea. Recruiting

2025-523864-19-00 Phase II 1 country IADADEMSTAT
Study of IADADEMSTAT for the Treatment of Sickle Cell Disease. Recruiting

2025-521838-29-00 Phase I (Other) 1 country
A Clinical trial to evaluate the efficacy of vafidemstat in negative symptoms and cognitive impairment associated with schizophrenia. (EVOLU… Recruiting

2023-507372-42-00 Phase II 5 countries VAFIDEMSTAT

Showing 1–4 of 4 trials

← All sponsors A–Z